Biomarin Pharmaceutical reported a net loss of $122.83 million for the three months ended Sep 30, 2026.

Form: 10-Q
Filed: Nov 3, 2026, 4:34 pm ET
Importance: Notable
Accession: 0001048477-26-000023

Revenue of $1.03 billion for the three months ended Sep 30, 2026.
Net loss of $122.83 million for the three months ended Sep 30, 2026.
Diluted EPS of -$0.63 for the three months ended Sep 30, 2026.
Cash and equivalents of $736.01 million as of Sep 30, 2026.

Written from the 10-Q on EDGAR. Check the filing before you rely on it.

Open in the app Get the app View on EDGAR

The reading, claim by claim

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.
For the quarter ended September 30, 2026, BIOMARIN PHARMACEUTICAL INC reported: Revenue $1.0 billion.
Net income -$122.8 million.

3 of 5 claims matched the filing text.

Not found in the filing text

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.
The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

From the filing's financial data, not stated in its text

From this 10-Q's financial data (XBRL) for the quarter ended September 30, 2026

Gross margin 80.0%.
Operating margin -8.0%.
Net margin -12.0%.
Revenue change from a year earlier +32.0%.

From the filing

Item 1. Financial Statements

BIOMARIN PHARMACEUTICAL INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

Three and Nine Months Ended September 30, 2026 and 2025

(In thousands, except per share amounts) (unaudited)

Three Months Ended

September 30, Nine Months Ended

September 30,

2026 2025 2026 2025 REVENUES: Net product revenues $ 1,013,080² $ 760,812 $ 2,757,551 $ 2,308,438 Royalty and other revenues 11,566 15,321 23,011 38,250 Total revenues 1,024,646 776,133 2,780,562 2,346,688 OPERATING EXPENSES: Cost of sales 205,416 140,085 603,210 441,733 Research and development 180,525 188,515 566,273 508,554

Acquired in-process research and development (IPR&D)

287,685 220,963 287,685 220,963 Selling, general and administrative 333,643 268,415 987,482 706,810 Intangible asset amortization 99,458 4,847 177,433 14,540 Total operating expenses 1,106,727 822,825 2,622,083 1,892,600

INCOME (LOSS) FROM OPERATIONS

( 82,081 ) ( 46,692 ) 158,479 454,088 Interest income 4,630 17,854 37,670 55,694 Interest expense ( 55,628 ) ( 2,579 ) ( 133,881 ) ( 8,121 )

Other income, net

1,310 5,093 8,550 7,972

INCOME (LOSS) BEFORE INCOME TAXES

( 131,769 ) ( 26,324 ) 70,818 509,633

Provision for (benefit from) income taxes

( 8,938 ) 4,420 43,360 114,159

NET INCOME (LOSS)³

$ ( 122,831³ ) $ ( 30,744 ) $ 27,458 $ 395,474

EARNINGS (LOSS) PER SHARE, BASIC

$ ( 0.63 ) $ ( 0.16 ) $ 0.14 $ 2.06

EARNINGS (LOSS) PER SHARE, DILUTED

$ ( 0.63 ) $ ( 0.16 ) $ 0.14 $ 2.04 Weighted average common shares outstanding, basic 193,590 192,032 193,171 191,639 Weighted average common shares outstanding, diluted 193,590 192,032 195,214 196,893 COMPREHENSIVE INCOME (LOSS) $ ( 118,059 ) $ ( 20,116 ) $ 36,920 $ 299,884

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.¹

BIOMARIN PHARMACEUTICAL INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

September 30, 2026 and December 31, 2025

(In thousands, except share amounts)

September 30, 2026 December 31, 2025

ASSETS (unaudited)

Current assets:

Cash and cash equivalents $ 736,007 $ 1,311,679

Short-term investments — 248,930

Accounts receivable, net 1,076,355 908,214 Inventory 1,796,069 1,298,883 Other current assets 312,205 185,784 Total current assets 3,920,636 3,953,490

Noncurrent assets:

Long-term investments — 492,242

Property, plant and equipment, net 980,081 952,508

Intangible assets, net 4,777,247 213,837 Goodwill 666,367 196,199 Deferred tax assets 897,787 1,508,697 Other assets 327,113 277,049 Total assets $ 11,569,231 $ 7,594,022

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable and accrued liabilities $ 946,107 $ 759,031

Current portion of long-term debt, net 658,717 —

Total current liabilities 1,604,824 759,031 Noncurrent liabilities: Long-term debt, net 3,514,974 597,176 Other long-term liabilities 193,401 150,816 Total liabilities 5,313,199 1,507,023 Stockholders' equity: Common stock, $ 0.001 par value: 500,000,000 shares authorized; 193,676,831 and 192,300,101 shares issued and outstanding, respectively 194 192 Additional paid-in capital 6,089,036 5,956,582

Company common stock held by the Nonqualified Deferred Compensation Plan ( 10,851 ) ( 10,508 )

Accumulated other comprehensive loss

( 4,011 ) ( 13,473 )

Retained earnings

181,664 154,206 Total stockholders' equity 6,256,032 6,086,999

Total liabilities and stockholders' equity $ 11,569,231 $ 7,594,022

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

BIOMARIN PHARMACEUTICAL INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

Three and Nine Months Ended September 30, 2026 and 2025

(In thousands) (unaudited)

Three Months Ended

September 30, Nine Months Ended

September 30,

2026 2025 2026 2025

Shares of common stock, beginning balances (1)

193,535 192,002 192,300 190,761 Issuances under equity incentive plans 142 97 1,377 1,338 Shares of common stock, ending balances 193,677 192,099 193,677 192,099

Total stockholders' equity, beginning balances (1)

$ 6,321,691 $ 6,027,113 $ 6,086,999 $ 5,657,990

Common stock:

Beginning balances (1)

194 192 192 191

Issuances under equity incentive plans, net of tax — — 2 1

Ending balances 194 192 194 192

Additional paid-in capital:

Beginning balances (1)

6,037,020 5,851,637 5,956,582 5,802,068 Issuances under equity incentive plans, net of tax ( 4,790 ) ( 2,779 ) ( 37,730 ) ( 46,218 ) Stock-based compensation 57,189 52,493 169,841 145,054

Change in Common stock held by the Nonqualified Deferred Compensation plan (NQDC)

( 383 ) ( 383 ) 343 64 Ending balances 6,089,036 5,900,968 6,089,036 5,900,968

Company common stock held by the NQDC:

Beginning balances (1)

( 11,234 ) ( 11,674 ) ( 10,508 ) ( 11,227 ) Common stock held by the NQDC 383 383 ( 343 ) ( 64 ) Ending balances ( 10,851 ) ( 11,291 ) ( 10,851 ) ( 11,291 )

Accumulated other comprehensive loss:

Beginning balances (1)

( 8,783 ) ( 44,565 ) ( 13,473 ) 61,653

Other comprehensive income (loss)

4,772 10,628 9,462 ( 95,590 ) Ending balances ( 4,011 ) ( 33,937 ) ( 4,011 ) ( 33,937 )

Retained earnings (accumulated deficit)

Beginning balances (1)

304,495 231,523 154,206 ( 194,695 ) Net income (loss) ( 122,831 ) ( 30,744 ) 27,458 395,474 Ending balances 181,664 200,779 181,664 200,779

Total stockholders' equity, ending balances

$ 6,256,032 $ 6,056,711 $ 6,256,032 $ 6,056,711

(1) The beginning balances for the nine-month periods were derived from the audited Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 26, 2026.

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

BIOMARIN PHARMACEUTICAL INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Nine Months Ended September 30, 2026 and 2025

(In thousands) (unaudited)

Nine Months Ended

September 30,

2026 2025 CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ 27,458 $ 395,474

Adjustments to reconcile net income to net cash provid

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
Repligen RGEN public float $6.0B, Jun 30, 2025
Madrigal Pharmaceuticals MDGL public float $5.6B, Jun 30, 2025

Get an email when BioMarin Pharmaceutical files

The reading, claim by claim

Not found in the filing text

From the filing's financial data, not stated in its text

From the filing

Item 1. Financial Statements

Similar companies